| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Subhash Varma | |
| Deepesh Lad | |||
| Arihant Jain | |||
| P2860 | cites work | Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders | Q74129093 |
| Annexin II and bleeding in acute promyelocytic leukemia | Q74659533 | ||
| Central venous line-related thrombosis in children: association with central venous line location and insertion technique | Q78863076 | ||
| Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation | Q79952965 | ||
| Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features | Q80166462 | ||
| The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment | Q81064713 | ||
| Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation | Q81309721 | ||
| Dysfunction of the PI3 kinase/Rap1/integrin α(IIb)β(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia | Q85657160 | ||
| Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation | Q86016806 | ||
| Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH | Q87016000 | ||
| Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders | Q24186028 | ||
| Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia | Q24187024 | ||
| Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation | Q24187751 | ||
| Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 | ||
| Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis | Q27005043 | ||
| Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera | Q28174281 | ||
| Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia | Q28182916 | ||
| Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer | Q28186303 | ||
| All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia | Q28324386 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. | Q30241189 | ||
| Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thro | Q30315531 | ||
| Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. | Q32061751 | ||
| Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q33336231 | ||
| Acute arterial thrombosis in acute promyelocytic leukaemia | Q33349243 | ||
| Hemorrhagic complications in pediatric hematologic malignancies | Q33375383 | ||
| Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy | Q33375921 | ||
| Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study | Q33378351 | ||
| Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy | Q33383664 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center | Q33419224 | ||
| Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment | Q33422300 | ||
| Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review | Q33436416 | ||
| Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study | Q33439387 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Disseminated intravascular coagulation in acute leukemia | Q34461307 | ||
| Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial | Q34522156 | ||
| Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. | Q34543068 | ||
| Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet | Q34597535 | ||
| Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity | Q35606202 | ||
| Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. | Q35609144 | ||
| Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1 | Q35612515 | ||
| Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. | Q35615155 | ||
| Thrombosis in children with acute lymphoblastic leukemia Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment | Q35617836 | ||
| Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders | Q36205153 | ||
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36337598 | ||
| The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia | Q36831719 | ||
| Adverse effects on hemostatic function of drugs used in hematologic malignancies | Q36831728 | ||
| American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. | Q36984787 | ||
| Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia | Q37152911 | ||
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 | ||
| Disseminated intravascular coagulation in hematologic malignancies | Q37770990 | ||
| Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia | Q37807000 | ||
| Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel | Q37914185 | ||
| Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis | Q38050141 | ||
| Thrombosis in acute promyelocytic leukemia | Q38069751 | ||
| Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management | Q38100371 | ||
| Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis | Q38182770 | ||
| Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis | Q38279947 | ||
| Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. | Q38843190 | ||
| Management of venous thromboembolism in myeloproliferative neoplasms | Q39016723 | ||
| Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. | Q39023642 | ||
| Effect of leukapheresis on blood coagulation in patients with hyperleukocytic acute myeloid leukemia | Q39064178 | ||
| Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. | Q39306435 | ||
| Disseminated intravascular coagulation at diagnosis is a strong predictor for both arterial and venous thrombosis in newly diagnosed acute myeloid leukemia | Q39646760 | ||
| OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism | Q39781009 | ||
| How I treat hematologic emergencies in adults with acute leukemia | Q40283386 | ||
| Cancer procoagulant A: A factor X activating procoagulant from malignant tissue | Q40307481 | ||
| Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management | Q40418584 | ||
| Venous thromboembolism in patients with chronic lymphocytic leukemia. | Q40431314 | ||
| Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea | Q40560173 | ||
| The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. | Q41121693 | ||
| Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. | Q41552439 | ||
| Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage | Q42283596 | ||
| Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. | Q42510695 | ||
| Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration | Q44272076 | ||
| Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms | Q44373577 | ||
| Cardiovascular events and intensity of treatment in polycythemia vera | Q44793541 | ||
| The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination | Q45029985 | ||
| Acquired hemophilia in chronic lymphocytic leukemia | Q45867901 | ||
| Thrombotic complications of polycythemia vera | Q46214484 | ||
| Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. | Q48002876 | ||
| A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with | Q48412454 | ||
| The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols | Q49697799 | ||
| Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia. | Q50972621 | ||
| Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. | Q53063495 | ||
| Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. | Q53348197 | ||
| The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. | Q55021823 | ||
| Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and O | Q56960816 | ||
| Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL stu | Q56992323 | ||
| THROMBIN GENERATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: Effect of Leukemia Immunophenotypic Subgroups | Q57985127 | ||
| Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? | Q58411876 | ||
| Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera | Q58411917 | ||
| Cancer procoagulant in acute lymphoblastic leukemia | Q59697248 | ||
| Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments | Q61050105 | ||
| Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism | Q61936450 | ||
| The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia | Q67687805 | ||
| Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia | Q67945625 | ||
| A new procoagulant in acute leukemia | Q68308908 | ||
| Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome | Q68915441 | ||
| Apoptosis is associated with increased cell surface tissue factor procoagulant activity | Q71421840 | ||
| Effect of prednisolone on the coagulation and fibrinolytic systems | Q71514700 | ||
| Thrombosis in cancer patients treated with hematopoietic growth factors--a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH | Q71553076 | ||
| Acquired von Willebrand disease in patients with high platelet counts | Q73917212 | ||
| Elastase mediated fibrinolysis in acute promyelocytic leukemia | Q74006092 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 61-72 | |
| P577 | publication date | 2017-09-18 | |
| P1433 | published in | Blood and lymphatic cancer : targets and therapy | Q27724575 |
| P1476 | title | Complications and management of coagulation disorders in leukemia patients | |
| P478 | volume | 7 |
| Q89878766 | Benzoxazole Derivative K313 Induces Cell Cycle Arrest, Apoptosis and Autophagy Blockage and Suppresses mTOR/p70S6K Pathway in Nalm-6 and Daudi Cells | cites work | P2860 |
Search more.